Erbitux news from FiercePharma
NewsMore NICE debate over cancer meds
It's not just Roche that refused to fork over cost-effectiveness info on its cancer med to the U.K.'s National Institution for Clinical Health and Excellence. So, too, has Merck Serono. Yesterday, Read more...
Erbitux, KRAS gene star at ASCO
As expected, headlines have been spewing from the American Society of Clinical Oncology meeting like ash from a volcano. And as promised, we bring you a roundup of the latest and greatest on using Read more...
BMS swallows Canada's Erbitux price
Call it a new pricing strategy. Bristol-Myers Squibb is preparing to launch the cancer treatment Erbitux in Canada after a two-year wrangle over cost. Approved by Health Canada in September 2005, Read more...
ALSO NOTED: Novo Nordisk creating 400 NJ jobs; Schering to sell off animal products;
> GlaxoSmithKline is acquiring Cambridge, MA-based Sirtris Pharmaceuticals for $720 million. GSK will pay $22.50 per share for the company. Read more...
Stanley: Erbitux outperformed Avastin
Morgan Stanley got a juicy scoop on the Avastin versus Erbitux boxing match: Genentech's Avastin faces news that as-yet-unpublished data shows Erbitux delivering an "unexpected survival Read more...
Avastin, Erbitux side effects probed
Researchers figured out how two different cancer drugs--Avastin and Erbitux--might lead to side effects. Made by Genentech, Avastin can cause kidney damage in some people. And Erbitux, sold by Read more...
BMS, AZ, Wyeth report earnings
A handful of drug makers released their earnings, and it's a mixed bag: some up, some down, some hit by one-time charges. Here's a roundup.Read more...
ImClone goes long on Erbitux
Is all the Erbitux hype warranted? Some industry analysts say yes, others say they're skeptical. The right answer carries big stakes, because ImClone Systems has all its short-term eggs in that Read more...
ALSO NOTED: Erbitux surge doesn't produce ImClone profit; Glenmark to sell MeyerZall drugs in S. Africa;
> Despite rising Erbitux sales, ImClone Systems lost $916,000 in the third quarter; the culprit was higher operating costs, including a $50 million charge for a patent lawsuit settlement. Read more...
SPOTLIGHT: Merck KGaA leads team to sell Erbitux in Japan
Merck KGaA leads team to sell Erbitux in Japan Call it a trifecta: ImClone Systems, Bristol-Myers Squibb and Merck KGaA are joining together to develop and market ImClone's cancer drug Erbitux in Read more...
| Press ReleasesPRESS RELEASE: ImClone and BMS Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan ImClone Systems and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan NEW YORK, Oct. 17 -- ImClone Systems Incorporated and Read more... PRESS RELEASE: ImClone Systems Says Broader US Label for Erbitux Colorectal Cancer Drug ImClone Systems Says Broader US Label for Erbitux Colorectal Cancer Drug NEW YORK, Oct. 2 -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that the U.S. Food and Read more... PRESS RLEASE: Repligen Announces Settlement with ImClone in Erbitux Lawsuit Repligen Announces Settlement with ImClone in Erbitux Lawsuit WALTHAM, MA - September 10, 2007 - Repligen Corporation announced today it has reached a settlement with ImClone Systems, Incorporated Read more... PRESS RELEASE: ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study; Shares Soar NEW YORK -- ImClone Systems Incorporated and Bristol-Myers Squibb Company (NYSE: BMY - Read more... |
Get more Erbitux coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends